| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Lori Lyons-Williams is Director at RAPT. Lori Lyons-Williams's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider.
Lori Lyons-Williams has 9 Form 4 filings on record from November 2021 to June 2026, across 2 companies: Director at Contineum Therapeutics (CTNM), 2024–2026; Director at RAPT Therapeutics (RAPT), 2021–2026.
The 14 reported transactions were 8 option or other derivative awards, 5 dispositions back to the company and 1 tender.
There are no priced open-market purchases or sales on record, so none of these filings shows a decision to buy or sell shares in the market.
No transactions found
Try adjusting your filters or search criteria